search
Back to results

The Effects of Leucine on Body Weight

Primary Purpose

Overweight, Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
L-Leucine 8gr
Liquid meal
L-Leucine 4g
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overweight focused on measuring Leucine, Weight Loss

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18-65 year old overweight/obese
  • healthy men and women
  • Body Mass Index (BMI) of 28-35

Exclusion Criteria:

  • unusual or extreme dietary or exercise habits
  • daily leucine supplement use
  • inability to follow instructions to drink liquid meals
  • type 1 diabetes or type 2 diabetes on drug treatment(diet controlled diabetics will be enrolled after consulting with their treating physicians)
  • hypothyroidism or hyperthyroidism
  • chronic wasting diseases (Acquired Immune Deficiency Syndrome (AIDS), cancers, cirrhosis, renal failure, Chronic Obstructive Pulmonary Disease (COPD), heart failure)
  • drug or alcohol abuse
  • tobacco smoker within the past 6 months
  • pregnancy or lactating
  • use of medications known to affect carbohydrate or lipid metabolism, satiety, or hunger
  • anemia
  • abnormal liver function tests (LFTs)
  • women who are of child bearing age without adequate birth control modality

Sites / Locations

  • Columbia University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

L-Leucine 4grams

L-Leucine 8 grams

L-Leucine 0 grams

Arm Description

This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.

Arm number two of the study will be a dose of Leucine of 8g.

The third arm of the study will be composed of a control drink with no leucine in it.

Outcomes

Primary Outcome Measures

Effects on Weight
Weight

Secondary Outcome Measures

Energy Expenditure

Full Information

First Posted
May 22, 2008
Last Updated
March 4, 2013
Sponsor
Columbia University
search

1. Study Identification

Unique Protocol Identification Number
NCT00683826
Brief Title
The Effects of Leucine on Body Weight
Official Title
Effects of Leucine Supplement on Body Weight and Cardiometabolic Changes
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Protein-rich diets appear to show some benefits in promoting weight loss. It is thought that increased intake of leucine may account for some of this effect. This study is designed to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply to humans. Specifically, our team would like to determine whether oral leucine supplementation in overweight/obese humans increases metabolic rate, reduces body weight, improves glucose utilization and/or, reduces circulating fat levels in the blood. We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This study will should provide data that can be used to design more definitive trials with regard to dietary leucine supplementation. Hypothesis This pilot study is designed to accomplish the following two goals: to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply in humans. Specifically, we want to determine whether oral leucine supplementation in overweight/obese individuals' increases basal metabolic rate, reduces body weight, improves glucose tolerance and/or insulin sensitivity, and/or reduces circulating Low-density Lipoprotein (LDL)-cholesterol levels. To provide data that can be used to design more definitive trials with regard to dietary leucine supplementation. We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This would in turn lead to more rigorous clinical trials involving larger sample sizes, and with diverse populations of different gender, age, and ethnic groups. Future trials may also be directed to determine minimal doses and durations of leucine supplementation that are capable of achieving clinically significant improvement in the cardio-metabolic risk profile in people.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity
Keywords
Leucine, Weight Loss

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
L-Leucine 4grams
Arm Type
Experimental
Arm Description
This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
Arm Title
L-Leucine 8 grams
Arm Type
Experimental
Arm Description
Arm number two of the study will be a dose of Leucine of 8g.
Arm Title
L-Leucine 0 grams
Arm Type
Placebo Comparator
Arm Description
The third arm of the study will be composed of a control drink with no leucine in it.
Intervention Type
Dietary Supplement
Intervention Name(s)
L-Leucine 8gr
Intervention Description
Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
Intervention Type
Other
Intervention Name(s)
Liquid meal
Intervention Description
Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
Intervention Type
Dietary Supplement
Intervention Name(s)
L-Leucine 4g
Intervention Description
Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
Primary Outcome Measure Information:
Title
Effects on Weight
Time Frame
4 weeks
Title
Weight
Time Frame
at the end of each study treatment arm (six weeks)
Secondary Outcome Measure Information:
Title
Energy Expenditure
Time Frame
will be measure at the end of each treatment period (6 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-65 year old overweight/obese healthy men and women Body Mass Index (BMI) of 28-35 Exclusion Criteria: unusual or extreme dietary or exercise habits daily leucine supplement use inability to follow instructions to drink liquid meals type 1 diabetes or type 2 diabetes on drug treatment(diet controlled diabetics will be enrolled after consulting with their treating physicians) hypothyroidism or hyperthyroidism chronic wasting diseases (Acquired Immune Deficiency Syndrome (AIDS), cancers, cirrhosis, renal failure, Chronic Obstructive Pulmonary Disease (COPD), heart failure) drug or alcohol abuse tobacco smoker within the past 6 months pregnancy or lactating use of medications known to affect carbohydrate or lipid metabolism, satiety, or hunger anemia abnormal liver function tests (LFTs) women who are of child bearing age without adequate birth control modality
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henry Ginsberg, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Effects of Leucine on Body Weight

We'll reach out to this number within 24 hrs